Revance Therapeutics, Inc.
33
1
3
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.1%
2 terminated/withdrawn out of 33 trials
92.9%
+6.4% vs industry average
27%
9 trials in Phase 3/4
38%
10 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
Role: collaborator
DaxibotulinumtoxinA for Blepharospasm
Role: collaborator
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
Role: lead
Open Label, 6-month Study for High Frequency and Chronic Migraine,
Role: collaborator
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
Role: collaborator
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Role: lead
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
Role: lead
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
Role: lead
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Role: lead
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Role: lead
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
Role: lead
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
Role: lead
Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
Role: lead
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Role: lead
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Role: lead
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
Role: lead
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
Role: lead
Teosyal RHA® Histology and Intradermal Implantation Evaluation Study
Role: lead
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Role: lead
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Role: lead